Sexually Transmitted Diseases

Although the incidence of Chlamydia trachomatis infections remains high among young women (ages 14-24), new data indicate that prevalence of the sexually-transmitted infection is decreasing.

Eric Daar, MD, explains how gene editing therapy can be used to move the HIV cure agenda forward.

A new study has uncovered how cytomegalovirus can bypass the body’s defense mechanisms that prevent viral infections.

Study results indicate that patients with HIV are willing to wait at least 19 hours or travel up to 28 miles to see a “nice” provider.

The FDA has approved 2 new treatments for HIV: a once-daily fixed-dose combination tablet of doravirine, lamivudine, and tenofovir disoproxil fumarate; and doravirine, a new NNRTI to be administered in combination with other antiretroviral medicines.

A new analysis from the CDC shows steep and sustained increases in STDs in recent years.

Two public health experts discuss the recent rapid increase in incidence of infectious diseases that has been linked with injection drug use.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

Colleen Kelley, MD, the biggest barriers to HIV prevention methods and how to overcome them.

Closing treatment gaps is critical to ending the HIV epidemic in the United States.

A new study reveals that the quadrivalent HPV catch-up vaccine was most effective against cancer risk in women who received the first dose between the ages of 14 and 20 years.

Medication advancements offer more options and formulations for treating pediatric patients living with HIV.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

New research from Johns Hopkins reveals that 2 genes, CMPK2 and BCLG, are selectively activated in the presence of type 1 interferon.

Use of ibalizumab in combination with other HIV treatment could be an effective option for adults with advanced drug-resistant HIV.

A phase 3 trial has met its primary endpoint, showing a similar efficacy of a once-a-month injectable 2DR of cabotegravir and rilpivirine compared to daily, oral 3DR.

The method uses genetic sequencing to pinpoint the source of new infections following a community intervention, therefore measuring the impact of the intervention.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

New research shows that incidences of suicidality were higher among patients who were prescribed EFV compared to a control group; the results indicate that EFV, rather that treatment initiation timelines, were correlated with suicidal behavior.

Syphilis continues to spread in indigenous populations residing in 4 jurisdictions throughout Australia.

Better diagnostics and treatment are needed for Mycoplasma genitalium—a lesser-known sexually-transmitted infection estimated to infect up to 3% of the population in many countries.

Science doesn’t support legal punishment of HIV-positive people.

A new CDC analysis underscores the need for HIV testing programs in the southern part of the United States to improve linkage medical care among HIV-positive black men who have sex with men (MSM).

Genital shedding in herpes patients is even more common than genital lesions. Can a new way of testing for the disease streamline the treatment process?

OSA is largely untreated in HIV patients, and this lack of treatment likely contributes to further comorbidity complications associated with the virus.

Eradication of HCV in patients with HIV results in reduction of CD4+ and CD8+ T cell immune activation.

At week 96, 73.1% of patients infected with HIV-1 and treated with once-daily doravirine + other ART medications, achieved viral suppression.

Investigators report results of the first randomized clinical trial to test a novel strategy to wake up and kill dormant HIV hiding in reservoir cells.

Dolutegravir and lamivudine combination regimen met primary endpoint in 2 phase 3 studies of treatment-naïve patients with HIV.

Mosaic-based vaccine regimen maintained humoral and cellular HIV immune responses according to long-term data from APPROACH.